Bharat WorldMeds charts India’s pharmaceutical exports. But the export story cannot be understood without the domestic market that underpins it — a $55 billion ecosystem serving 1.4 billion people, the third largest pharmaceutical market in the world by volume.
India’s pharmaceutical industry is sometimes described through its exports alone. That framing misses the foundation. The domestic market — approximately $55 billion as of 2025 — is nearly twice the size of the export market. It is the base from which India’s manufacturing scale, quality infrastructure, and competitive pricing originate.
India ranks 3rd globally by volume of pharmaceutical consumption and 11th by value, according to the Department of Pharmaceuticals (March 2026 factsheet). The gap between volume and value rankings captures the essential fact: India consumes enormous quantities of medicine at very low prices.
Over the past nine years, the domestic market has grown at a compound annual rate of 9.4%, driven by rising healthcare spending, expanding insurance coverage, and an increasing chronic disease burden in a population of 1.4 billion.
India’s domestic market is structured differently from any other major pharmaceutical market. Generic drugs account for approximately 97% of the market by value — only about 3% is patented/innovator drugs. But within that vast generics space, branded generics hold approximately 87% of the market.
This means Indian patients overwhelmingly buy medicines that are chemically identical to originator drugs, manufactured by Indian companies, sold under Indian brand names, at Indian prices. The result is a market where price competition is intense, brand loyalty exists at the pharmacy level, and the consumer benefits from both.
The domestic market is not separate from the export story — it is the engine that makes exports possible. Three connections are critical:
Estimates of India’s domestic pharmaceutical market vary depending on scope and methodology. The most commonly cited government-adjacent figure is approximately $55 billion (2025), from Bain & Company via IBEF. Other estimates range from $43 billion to $72 billion depending on whether APIs, bulk drugs, and contract manufacturing are included.
| Source | Estimate (2025) | Scope |
|---|---|---|
| Bain & Company / IBEF | ~$55 billion | Domestic formulations market |
| Mordor Intelligence | $57.6 billion | Pharmaceutical market |
| Fortune Business Insights | $72.2 billion | Broader pharma + biotech |
| Grand View Research | $42.9 billion | Pharmaceutical market (narrow) |